Organogenesis Holdings Inc. (ORGO)
NASDAQ$5.01
Market Cap
$635.41M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
761 of 924
Rank in Industry
45 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ORGO Insider Trading Activity
ORGO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,485,681 | 8 | 100 |
Related Transactions
| Driscoll Michael Joseph | director | 0 | $0 | 1 | $127,535 | $-127,535 |
| Gillheeney Gary S. | President and CEO | 0 | $0 | 7 | $1.36M | $-1.36M |
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that …
Insider Activity of Organogenesis Holdings Inc.
Over the last 12 months, insiders at Organogenesis Holdings Inc. have bought $0 and sold $1.49M worth of Organogenesis Holdings Inc. stock.
On average, over the past 5 years, insiders at Organogenesis Holdings Inc. have bought $13.99M and sold $35.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,000 shares for transaction amount of $7,680 was made by KATZ MICHAEL W (director) on 2022‑11‑21.
List of Insider Buy and Sell Transactions, Organogenesis Holdings Inc.
| 2025-03-04 | Sale | Driscoll Michael Joseph | director | 25,000 0.02% | $5.10 | $127,535 | +4.37% | |
| 2024-12-16 | Sale | Gillheeney Gary S. | President and CEO | 5,585 0.0042% | $3.49 | $19,492 | -1.41% | |
| 2024-12-13 | Sale | Gillheeney Gary S. | President and CEO | 55,615 0.0414% | $3.36 | $186,866 | +3.38% | |
| 2024-12-12 | Sale | Gillheeney Gary S. | President and CEO | 43,359 0.0332% | $3.55 | $153,924 | -0.85% | |
| 2024-12-11 | Sale | Gillheeney Gary S. | President and CEO | 157,448 0.1179% | $3.64 | $573,111 | -3.96% | |
| 2024-12-10 | Sale | Gillheeney Gary S. | President and CEO | 58,525 0.044% | $3.64 | $213,031 | -4.08% | |
| 2024-12-09 | Sale | Gillheeney Gary S. | President and CEO | 41,052 0.031% | $3.52 | $144,503 | +0.86% | |
| 2024-12-06 | Sale | Gillheeney Gary S. | President and CEO | 18,416 0.0139% | $3.65 | $67,218 | -4.08% | |
| 2024-01-10 | Sale | ERANI ALBERT | 10 percent owner | 17,972 0.0143% | $4.28 | $76,875 | -28.43% | |
| 2024-01-09 | Sale | ERANI ALBERT | 10 percent owner | 197,921 0.1518% | $4.37 | $863,985 | -32.56% | |
| 2023-04-12 | Sale | ERANI ALBERT | 10 percent owner | 50,000 0.0384% | $2.07 | $103,545 | +43.69% | |
| 2023-04-12 | Sale | ERANI ALBERT | 10 percent owner | 25,000 0.0192% | $2.07 | $51,773 | +43.69% | |
| 2022-11-21 | KATZ MICHAEL W | director | 3,000 0.0023% | $2.56 | $7,680 | +0.77% | ||
| 2022-11-18 | KATZ MICHAEL W | director | 3,000 0.0023% | $2.57 | $7,710 | +1.35% | ||
| 2022-08-12 | Leibowitz Arthur S | 3,000 0.0023% | $4.75 | $14,265 | -38.14% | |||
| 2022-08-12 | Driscoll Michael Joseph | 5,000 0.0039% | $4.80 | $24,000 | -38.14% | |||
| 2022-06-09 | Sale | Wisdom Starr | 29,669 0.0219% | $4.89 | $145,081 | -40.39% | ||
| 2022-06-09 | Sale | Erani Dennis | 29,669 0.0219% | $4.89 | $145,081 | -40.39% | ||
| 2022-06-06 | Sale | Erani Dennis | 50,000 0.0394% | $5.49 | $274,500 | -43.49% | ||
| 2022-06-06 | Sale | Wisdom Starr | 20,000 0.0155% | $5.39 | $107,800 | -43.49% |
Total: 112
*Gray background shows transactions not older than one year
Insider Historical Profitability
26.09%
| Driscoll Michael Joseph | director | 166879 0.1316% | $836,063.79 | 1 | 1 | <0.0001% |
| Ades Alan A. | 59836745 47.1794% | $299.78M | 5 | 2 | +41.74% | |
| NUSSDORF GLENN H | 59448027 46.873% | $297.83M | 6 | 2 | +28.07% | |
| GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 | 10 percent owner | 59448027 46.873% | $297.83M | 1 | 0 | <0.0001% |
| Avista Capital Managing Member IV, LLC | 29924515 23.5946% | $149.92M | 18 | 0 | +53.22% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$187,390,806 | 89 | 12.63% | $777.44M | |
$12,681,496 | 70 | 20.90% | $804.92M | |
$218,350,131 | 64 | 16.68% | $296.77M | |
Organogenesis Holdings Inc. (ORGO) | $129,489,279 | 57 | 26.09% | $635.41M |
$33,884,330 | 45 | 12.50% | $398.62M |
ORGO Institutional Investors: Active Positions
| Increased Positions | 64 | +52.46% | 5M | +7.7% |
| Decreased Positions | 50 | -40.98% | 6M | -9.92% |
| New Positions | 22 | New | 953,389 | New |
| Sold Out Positions | 16 | Sold Out | 1M | Sold Out |
| Total Postitions | 136 | +11.48% | 63M | -2.22% |
ORGO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Soleus Capital Management, L.P. | $77,531.00 | 9.83% | 12.48M | +645,000 | +5.45% | 2024-12-31 |
| Morgan Stanley | $73,468.00 | 9.32% | 11.83M | -139,157 | -1.16% | 2024-12-31 |
| Blackrock, Inc. | $32,764.00 | 4.15% | 5.28M | -53,391 | -1% | 2024-12-31 |
| Vanguard Group Inc | $22,293.00 | 2.83% | 3.59M | -82,636 | -2.25% | 2024-12-31 |
| Acadian Asset Management Llc | $19,156.00 | 2.43% | 3.08M | +65,655 | +2.17% | 2024-12-31 |
| Assenagon Asset Management S.A. | $18,325.00 | 2.32% | 2.95M | +1M | +54.03% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $17,321.00 | 2.2% | 2.79M | +442,772 | +18.87% | 2024-12-31 |
| Deutsche Bank Ag | $15,213.00 | 1.93% | 2.45M | -2M | -49.42% | 2024-12-31 |
| Geode Capital Management, Llc | $10,791.00 | 1.37% | 1.74M | -7,694 | -0.44% | 2024-12-31 |
| State Street Corp | $9,654.00 | 1.22% | 1.55M | +94,744 | +6.49% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.